Rugiet Expands Its Health Offerings
References: businesswire
Rugiet — a men's health company that surpassed 100 million dollars in revenue in 2025 and has treated over $400,000 — has launched a testosterone replacement therapy program that includes enclomiphene as well as oral, injectable, and topical options. This service is supported by comprehensive lab testing, physician evaluations, and individualized treatment plans for qualified patients.
Rugiet, which is best known for its three-in-one erectile dysfunction treatment called Ready, also introduced a new brand identity created with Pentagram and Alright Studio to signal its evolution into a broader performance-driven healthcare company for men.
The expansion of the testosterone replacement therapy program comes as research has documented generational declines in testosterone levels independent of aging, and a 2024 study found that prescription of testosterone treatments increased significantly among younger men.
Image Credit: Rugiet
Rugiet, which is best known for its three-in-one erectile dysfunction treatment called Ready, also introduced a new brand identity created with Pentagram and Alright Studio to signal its evolution into a broader performance-driven healthcare company for men.
The expansion of the testosterone replacement therapy program comes as research has documented generational declines in testosterone levels independent of aging, and a 2024 study found that prescription of testosterone treatments increased significantly among younger men.
Image Credit: Rugiet
Trend Themes
1. Direct-to-consumer Hormone Care - A shift toward accessible, physician-supervised testosterone programs with remote evaluations and lab integration opens room for vertically integrated care models that bundle diagnostics, treatment, and follow-up.
2. Performance-driven Men's Health Branding - Brand repositioning from niche sexual-health products to broader male performance care signals potential for product ecosystems that connect clinical services with lifestyle and wellness offerings.
3. Younger Demographic Testosterone Uptake - Rising prescriptions among younger men amid population-level declines in testosterone indicate demand for age-specific protocols, long-term monitoring, and preventive interventions.
Industry Implications
1. Telemedicine Prescriptive Platforms - Online clinical platforms that combine telehealth visits, e-prescribing, and integrated lab ordering are poised to alter traditional clinic referral flows and medication access pathways.
2. Diagnostic Lab Services - Comprehensive lab testing tied to hormone therapies creates opportunities for specialized labs offering rapid, longitudinal endocrine panels and predictive biomarker analytics.
3. Pharmaceutical Formulation and Delivery - Demand for oral, injectable, topical, and selective-agent options like enclomiphene highlights prospects for novel delivery formats, combination formulations, and personalized dosing technologies.
7
Score
Popularity
Activity
Freshness
